News

News and Press Releases
Advocacy The CF Foundation’s 16th Annual Teen Advocacy Day Empowers Teens to Make Their Voice Heard

More than 70 teens from across the country — a third of whom live with cystic fibrosis — urged their members of Congress to pass the PASTEUR Act before the end of the year.

July 2, 2024 | 4 min read
Care Team Cystic Fibrosis Community Perspectives Influence Future of CF Care Model

Community feedback highlights the importance of CF care teams, in-person CF care, and telehealth.

May 7, 2024 | 4 min read
CF Foundation Announces New Chairs of Milestones III Campaign

Long-standing volunteers Kate O’Donnell and Amy Barry to co-chair major gift and planned giving campaign, continuing the legacy of beloved philanthropic leader Joe O’Donnell

April 18, 2024 | 4 min read
Clinical Trials | Our Research Approach CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.

April 3, 2024 | 3 min read
Patient Registry CF Foundation Adapts Registry Reporting to New Race-Neutral Standards

Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.

April 2, 2024 | 5 min read
Our Advocacy Work Nearly 350 Advocates Urge Congressional Action During 17th Annual March on the Hill

This year’s program marked the largest in-person advocacy event in the Foundation’s history.

March 19, 2024 | 3 min read
Our Research Approach Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX

Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.

March 18, 2024 | 2 min read
Our Research Approach Cystic Fibrosis Foundation Invests More Than $6.6 Million in Additional Funding in Sionna Therapeutics

The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.

March 7, 2024 | 2 min read
About the CF Foundation Bruce Marshall, Chief Medical Officer, to Retire From the CF Foundation

A transformative leader for more than two decades, Marshall will transition to advisory role

March 6, 2024 | 3 min read
Our Research Approach Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine’s prime editing technology has the potential to bring genetic therapies to all people with cystic fibrosis, ultimately paving the way to a cure.

Jan. 25, 2024 | 4 min read